Resultados da pesquisa - Portal para modelos de dados médicos (portal MDM)

Filtrar os resultados da pesquisa
Selecionar modelos de dados

Modelos de dados selecionados

Deve ter sessão iniciada para selecionar vários modelos de dados e para os transferir ou analisar.

42 Resultados da pesquisa.

dbGaP phs001244 Nasopharynx Cancer Whole Exome Sequencing - Eligibility

- 06/04/2023 - 5 Formulários, 1 Grupo de itens, 1 Elemento de dados, 1 Idioma

Grupo de itens: IG.elig

Principal Investigator: Kwok-wai Lo, Chinese University of Hong Kong, Hong Kong, China MeSH: Nasopharyngeal Neoplasms https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001244 Nasopharyngeal carcinoma (NPC) is an aggressive head and neck cancer characterized by Epstein-Barr virus (EBV) infection and dense lymphocyte infiltration. The scarcity of NPC genomic data hinders the understanding of NPC biology, disease progression, and rational therapy design. Here, we performed whole-exome sequencing (WES) on 111 micro-dissected EBV-positive NPCs, with 15 cases subjected to further whole-genome sequencing (WGS), to determine its mutational landscape. We identified enrichment for genomic aberrations of multiple negative regulators of the NF-kB pathway in a total of 41% of cases including CYLD, TRAF3, NFKBIA and NLRC5. Functional analysis confirmed novel inactivating CYLD mutations as drivers for NPC cell growth. The EBV oncoprotein latent member protein 1 (LMP1) functions to constitutively activate NF-kB signaling, and we observed mutual exclusivity among somatic NF-kB pathway aberrations and LMP1-overexpression, suggesting that NF-kB activation is selected for by both somatic and viral events during NPC pathogenesis.

Nasopharyngeal Neoplasms

pht006055.v1.p1

1 Grupo de itens 2 Elementos de dados

pht006056.v1.p1

1 Grupo de itens 3 Elementos de dados

pht006057.v1.p1

1 Grupo de itens 13 Elementos de dados

pht006058.v1.p1

1 Grupo de itens 4 Elementos de dados

Eligibility Nasopharyngeal Carcinoma NCT01271439

- 21/09/2018 - 1 Formulário, 2 Grupos de itens, 21 Elementos de dados, 1 Idioma

Grupos de itens: Inclusion Criteria, Exclusion Criteria

Study of Chemoradiotherapy Combined With Cetuximab in Nasopharyngeal Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT01271439 Collaborating Parties: Zhejiang Cancer Hospital Wenzhou Medical University The First Affiliate Hospital of Guangxi Medical College Xijing Hospital Hunan Cancer Hospital Jiangxi Provincial Cancer Hospital Wuhan Union Hospital, China Wuhan University Hubei Cancer Hospital Tongji University Cancer Hospital of Shantou University Shenzhen People's Hospital First People's Hospital of Foshan

Eligibility Local Advanced High Risk Nasopharyngeal Carcinoma NCT02143388

- 30/06/2020 - 1 Formulário, 2 Grupos de itens, 16 Elementos de dados, 1 Idioma

Grupos de itens: Inclusion Criteria, Exclusion Criteria

Concurrent Cisplatin Chemoradiation With or Without Capecitabine as Adjuvant Chemotherapy in Local Advanced High Risk Nasopharyngeal Carcinoma: Phase II Randomized Control Clinical Trial; ODM derived from: https://clinicaltrials.gov/show/NCT02143388

Eligibility Nasopharyngeal Carcinoma NCT00592501

- 01/06/2017 - 1 Formulário, 2 Grupos de itens, 19 Elementos de dados, 1 Idioma

Grupos de itens: Inclusion Criteria, Exclusion Criteria

Proton Radiotherapy With Chemotherapy for Nasopharyngeal Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT00592501

Eligibility Nasopharyngeal Carcinoma NCT02363400

- 22/05/2019 - 1 Formulário, 2 Grupos de itens, 19 Elementos de dados, 1 Idioma

Grupos de itens: Inclusion Criteria, Exclusion Criteria

A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA; ODM derived from: https://clinicaltrials.gov/show/NCT02363400

Eligibility Nasopharyngeal Carcinoma NCT02512315

- 21/05/2019 - 1 Formulário, 2 Grupos de itens, 13 Elementos de dados, 1 Idioma

Grupos de itens: Inclusion Criteria, Exclusion Criteria

A Trial On 4 Cycles Of Neoadjuvant Chemotherapy Plus Concurrent Chemoradiation In N2-3 Nasopharyngeal Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT02512315

Eligibility Nasopharyngeal Carcinoma NCT02460419

- 21/05/2019 - 1 Formulário, 2 Grupos de itens, 17 Elementos de dados, 1 Idioma

Grupos de itens: Inclusion Criteria, Exclusion Criteria

Maintenance Capecitabine Plus Best Supportive Care Versus Best Supportive Care for Metastatic Nasopharyngeal Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT02460419

Eligibility Nasopharyngeal Carcinoma NCT02016417

- 21/05/2019 - 1 Formulário, 2 Grupos de itens, 16 Elementos de dados, 1 Idioma

Grupos de itens: Inclusion Criteria, Exclusion Criteria

Induction Chemotherapy With GP Versus TPF in the Treatment of Advanced Nasopharyngeal Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT02016417

Eligibility Nasopharyngeal Carcinoma NCT00953420

- 26/09/2018 - 1 Formulário, 2 Grupos de itens, 18 Elementos de dados, 1 Idioma

Grupos de itens: Inclusion Criteria, Exclusion Criteria

Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes; ODM derived from: https://clinicaltrials.gov/show/NCT00953420

Eligibility Nasopharyngeal Carcinoma NCT02501993

- 08/01/2019 - 1 Formulário, 2 Grupos de itens, 9 Elementos de dados, 1 Idioma

Grupos de itens: Inclusion Criteria, Exclusion Criteria

Nasopharyngeal Carcinoma Screening in Zhongshan City; ODM derived from: https://clinicaltrials.gov/show/NCT02501993

Eligibility Nasopharyngeal Carcinoma NCT02328261

- 08/01/2019 - 1 Formulário, 2 Grupos de itens, 9 Elementos de dados, 1 Idioma

Grupos de itens: Inclusion Criteria, Exclusion Criteria

A Phase II Study of Icotinib in Treating Patients With Advanced Nasopharyngeal Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT02328261

Eligibility Nasopharyngeal Carcinoma NCT01417390

- 21/09/2018 - 1 Formulário, 2 Grupos de itens, 13 Elementos de dados, 1 Idioma

Grupos de itens: Inclusion Criteria, Exclusion Criteria

Study of Neoadjuvant Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT01417390

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.